Natural Products and some Semi-synthetic Analogues as Potential TRPV1 Ligands for Attenuating Neuropathic Pain

• Published in: Current pharmaceutical biotechnology Vol. 23; no. 6; p. 766
• Main Authors: Naik, Gaurav Gopal, Uniyal, Ankit, Chouhan, Deepak, Tiwari, Vinod, Sahu, Alakh N
• Format: Journal Article
• Language: English
• Published: Netherlands 01-01-2022
• Subjects: Biological Products - pharmacology; Biological Products - therapeutic use; Humans; Ligands; Neuralgia - drug therapy; Prospective Studies; Quality of Life; TRPV Cation Channels - physiology; TRPV Cation Channels - therapeutic use; antagonists; natural products; neuropathic pain; agonists; semi-synthetic analogues; TRPV1 channels
• ISSN: 1873-4316
• DOI: 10.2174/1389201022666210719155931

Natural products and leads inspired by them have acted as a probe for successful drug discovery for many decades. Pain is an obnoxious sensory and emotional experience associated with potential tissue damage. It affects the quality of life of patients to a greater extent. Despite the availability of several agents targeting TRP receptors, none of them can proficiently alleviate neuropathic pain. TRPV1 is a prospective target for treating neuropathic pain as it is recognized to modulate the pain circuitry at the periphery and the central level. In this review, we have discussed several natural molecules, such as Capsaicinoids, Capsinoids, Piperine, Eugenol, Scutigeral, Ginsenosides, Cinnamaldehyde, Camphor, Shogaol, Gingerols, Zingerone, Allicin, Evodiamine, Allylisothiocyanate, Cannabidiol, Ricinoleic acid, Isovelleral, Capsazepine, Thapsigargin, Pellitorine, Yohimbine, Curcumin and some semi-synthetic analogues that activate TRPV1 channels and consequently, can be further harnessed for the treatment of neuropathic pain.